4.6 Article

Basic fibroblast growth factor protects against influenza A virus-induced acute lung injury by recruiting neutrophils

期刊

JOURNAL OF MOLECULAR CELL BIOLOGY
卷 10, 期 6, 页码 573-585

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jmcb/mjx047

关键词

influenza H1N1 virus; recombinant FGF2 protein; neutrophil recruitment; FGFR2-PI3K-AKT-NF kappa B signaling; therapeutic target

资金

  1. National High Technology Research and Development Program of China [SS2015AA020924]
  2. National Natural Science Foundation of China [81771700]
  3. Ministry of Science and Technology of China [2013ZX10004003, SS2012AA020905]
  4. National Major Research and Development Program [2016YFA0502203, 2017YFC1200800]
  5. Beijing Nova Program [Z141107001814054]

向作者/读者索取更多资源

Influenza virus (IAV) infection is a major cause of severe respiratory illness that affects almost every country in the world. IAV infections result in respiratory illness and even acute lung injury and death, but the underlying mechanisms responsible for IAV pathogenesis have not yet been fully elucidated. In this study, the basic fibroblast growth factor 2 (FGF2) level was markedly increased in H1N1 virus-infected humans and mice. FGF2, which is predominately derived from epithelial cells, recruits and activates neutrophils via the FGFR2-PI3K-AKT-NF.B signaling pathway. FGF2 depletion or knockout exacerbated influenza-associated disease by impairing neutrophil recruitment and activation. More importantly, administration of the recombinant FGF2 protein significantly alleviated the severity of IAV-induced lung injury and promoted the survival of IAV-infected mice. Based on the results from experiments in which neutrophils were depleted and adoptively transferred, FGF2 protected mice against IAV infection by recruiting neutrophils. Thus, FGF2 plays a critical role in preventing IAV-induced lung injury, and FGF2 is a promising potential therapeutic target during IAV infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据